Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD

Non-invasive tests (NITs) facilitate the early diagnosis and management of clinically significant portal hypertension in patients with compensated advanced chronic liver disease (cACLD). In our contemporary cohort of patients with cACLD, mainly steatotic liver disease, recruited at 16 European expert centres, the hepatic venous pressure gradient and NITs were similarly predictive of decompensation within 1 to 2 years of follow-up. Serum albumin levels were identified as the second main predictor of decompensation after hepatic venous pressure gradient or NITs for clinically significant portal hypertension. Novel models were developed that could accurately predict the risk of decompensation, thereby refining point-of-care risk stratification and informing clinical trial design for patients with CTP-A cACLD.

Authors

Institutions

Publication Details

Journal
Journal of Hepatology
Published
2025-11-04
DOI
https://doi.org/10.1016/j.jhep.2025.10.019
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD

Mattias Mandorfer, Juan Carlos García‐Pagán, Emma Vanderschueren, Marı́a Isabel Torres et al.
Journal of Hepatology
Liver Disease and Transplantation
article

Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD

Mattias Mandorfer, Juan Carlos García‐Pagán, Emma Vanderschueren, Marı́a Isabel Torres, Shantha Valainathan, Olivier Roux, Philip Y. Attalla, Christian Labenz, José Presa, Bogdan Procopeț, Tomas Guasconi, Vincenza Calvaruso, Wilhelmus J. Kwanten, Ángela Puente, Luigi Colecchia, Paul Thöne, José Ignacio Fortea, Audrey Payancé, Elton Dajti, Monica Lupșor‐Platon, Carlos A. Pardo, Marcello Bianchini, Benjamin Maasoumy, Chloé De Broucker, Oana Nicoară-Farcău, José Luís Calleja, Thomas Vanwolleghem, Pierre‐Emmanuel Rautou, Filippo Schepis, Fanny Turón, Antonio Colecchia, Elba Llop, Horia Ştefănescu, Annalisa Berzigotti, Agustı́n Albillos, Angelo Armandi, Yuly P. Mendoza, Aitor Odriozola, Wim Laleman, Lisa Sandmann, Dario Saltini, Lucile Moga, Luís Téllez, Virginia Hernández–Gea, Thomas Reiberger, Albert Friedrich Stättermayer, Mathias Jachs, Petra Fischer, Federico Ravaioli, Michael A Trauner, Andreea Fodor, Luisa Vonghia, Jörn M. Schattenberg, Lotte Schoenmakers, Maria Grasso, Sven Francque, T. Issoufaly
article en

Abstract

Non-invasive tests (NITs) facilitate the early diagnosis and management of clinically significant portal hypertension in patients with compensated advanced chronic liver disease (cACLD). In our contemporary cohort of patients with cACLD, mainly steatotic liver disease, recruited at 16 European expert centres, the hepatic venous pressure gradient and NITs were similarly predictive of decompensation within 1 to 2 years of follow-up. Serum albumin levels were identified as the second main predictor of decompensation after hepatic venous pressure gradient or NITs for clinically significant portal hypertension. Novel models were developed that could accurately predict the risk of decompensation, thereby refining point-of-care risk stratification and informing clinical trial design for patients with CTP-A cACLD.

Journal of HepatologyVol. 84(4)
University of Bern (CH), University of Modena and Reggio Emilia (IT), Inserm (FR), Johannes Gutenberg University Mainz (DE), Université Paris Cité (FR), Iuliu Hațieganu University of Medicine and Pharmacy (RO), University Hospital of Bern (CH), Medizinische Hochschule Hannover (DE), Azienda Unita' Sanitaria Locale Di Modena (IT), Assistance Publique – Hôpitaux de Paris (FR), Marqués de Valdecilla University Hospital (ES), Antwerp University Hospital (BE), Hospital Universitario Puerta de Hierro Majadahonda (ES), Azienda Ospedaliero-Universitaria di Modena (IT), Department of Medical Sciences (RU), Instituto de Investigación Marqués de Valdecilla (ES), Azienda USL di Bologna (IT), Instituto Ramón y Cajal de Investigación Sanitaria (ES), Department of Medical Sciences (BY), Centre de Recherche sur l'Inflammation (FR), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Direção Geral do Território (PT), Hospital Universitario Ramón y Cajal (ES), Medical University of Vienna (AT), University of Palermo (IT), Saarland University (DE), KU Leuven (BE)
Openalex Percentile: Top 57%
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.